A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4).

Trial Profile

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZUMA-4
  • Sponsors Kite Pharma
  • Most Recent Events

    • 08 Aug 2017 According to a Kite Pharma media release, the company expects preliminary follow-up phase 1 data from ZUMA-3 and ZUMA-4 studies and advance these studies into phase 2 in the second half of 2017.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 25 Jun 2017 Updated results from the study (data cut off 19 Jan 2017) presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top